Press Releases
 
Non-Alcoholic Steatohepatitis Market To Reach Worth US$ 20,676.0 Mn By 2025

Non-Alcoholic Steatohepatitis Market Is Expected To Reach Worth US$ 20,676.0 Mn By 2025

United States, 12 July 2019 -- Non-Alcoholic Steatohepatitis Market Is Expected To Reach Worth US$ 20,676.0 Mn By 2025

According to the latest report published by Credence Research, Inc. “Non-Alcoholic Steatohepatitis Market – (Drug Type – Obeticholic Acid, Aramchol, Saroglitazar and Elafibranors): Market Growth, Future Prospects and Competitive Analysis, 2017-2025,” the market was valued at US$ 729.0 Mn in 2016, and is expected to reach US$ 20,676.0 Mn by 2025, expanding at a CAGR of 46.1% from 2017 to 2025.

Browse the full report Non-Alcoholic Steatohepatitis Market Growth, Future Prospects and Competitive Analysis, 2017-2025 at https://www.credenceresearch.com/report/non-alcoholic-steatohepatitis-market

Market Insights

Nonalcoholic Steatohepatitis (NASH) is the progressive form of Nonalcoholic Fatty Liver Disease (NAFLD), wherein excessive fat deposition causes inflammation and damage to the liver, eventually leading to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases. NASH affects around 2-5% of Americans and is considered to be one of the foremost causes of liver transplantation. Currently management of NASH includes lifestyle changes such as healthy diet, weight reduction and physical activity. Despite of growing treatment need there are no approved therapeutic for NASH. Some drugs are prescribed off-label such as Metformin which is used in type-2 diabetes and NASH. However, NASH therapeutics exhibit a lucrative pipeline with more than 20 drug candidates undergoing Phase II clinical trials. The most promising drug anticipated to enter the NASH market in the near future is Elafibranor (Genfit) and Obeticholic Acid (Intercept) which are undergoing phase III trials. Many pharma giants Allergan, Gilead Sciences, Novo Nordisk and Bristol-Myers Squibb are developing drugs for NASH which further boost the NASH market during the future period.

North America held the largest share in the global non-alcoholic steatohepatitis market. In U.S. more than 25% of the population is affected by NAFLD as mentioned by the America Liver Foundation. Moreover, the rate of obesity is increasing rapidly in the children and ##### in the U.S. which is a primary risk factor for NASH. Furthermore, aggressive research and clinical trials in the region would further boost the non-alcoholic steatohepatitis market. According to the British Liver Trust, Non-Alcoholic Fatty Liver Disease (NAFLD) is considered to be the most common liver problem in the Western world, affecting 20-30% of the population. Asia Pacific is one of the fastest growing NASH market due to alarming increase in the obesity rates in the region due to rising lifestyle changes. Moreover, the increasing number of research & development and supportive regulations are favouring the growth of non-alcohol steatohepatitis market.

Market Competition Assessment:

The non-alcoholic steatohepatitis market has major pharmaceutical companies such as Gilead Sciences, Novo Nordisk, and Bristol-Myers Squibb developing drugs for NASH or its consequences, with Allergan the latest to enter the space. Allergan acquired Tobira Therapeutics Inc. and Akarna Therapeutics Ltd. in the second half of 2016. These acquisitions provide Allergan a readymade pipeline for the potentially lucrative NASH market.

Key Market Movements:

- Lucrative pipeline for NASH market with more than 20 molecules undergoing clinical trials would boost the demand for NASH market.

- Alarming rise in the diabetes and obesity prevalence would act as a driving factor for the growth of the NASH market.

Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58580

Table of Content

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Non-Alcoholic Steatohepatitis Market Portraiture
2.2 Non-Alcoholic Steatohepatitis Market, by Drug Type, 2016 (US$ Mn)
2.3 Non-Alcoholic Steatohepatitis Market, by Geography, 2016 (Value %)

Chapter 3 Global Non-Alcoholic Steatohepatitis Market Analysis
3.1 Global Non-Alcoholic Steatohepatitis Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Lucrative Pipeline for NASH Therapeutics
3.2.1.2 Alarming rise in the diabetic and Obese Population Globally
3.2.2 Challenges
3.2.2.1 High Prices of the drug considering the long duration of the treatment
3.2.2.2 Minimum Diagnostic Techniques for NASH
3.2.3 Opportunities
3.2.3.1 NASH Biomarker Development
3.3 Attractive Investment Proposition
3.4 Competitive Analysis: Global Non-Alcoholic Steatohepatitis Market, 2016 (Value %)

Chapter 4 Global Non-Alcoholic Steatohepatitis Market Analysis, By Drug Type
4.1 Overview
4.1.1 Market Attractive Proposition of Non-Alcoholic Steatohepatitis Market, by Drug Type, 2016
4.2 Obeticholic Acid
4.3 Aramchol
4.4 Saroglitazar
4.5 Elafibranor

Chapter 5 Global Non-Alcoholic Steatohepatitis Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Non-Alcoholic Steatohepatitis Market, by Drug Type, 20152025 (US$ Mn)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015-2025 (US$ Mn)
5.4 Asia-Pacific (China, Japan & Rest of Asia-Pacific)
5.4.1 Asia Pacific Non-Alcoholic Steatohepatitis Market, by Drug Type, 20152025 (US$ Mn)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Non-Alcoholic Steatohepatitis Market, by Drug Type, 20152025 (US$ Mn)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015-2025 (US$ Mn)

Chapter 6 Company Profiles
6.1 AstraZeneca plc
6.2 Intercept Pharmaceutical Inc.
6.3 Galmed Pharmaceuticals
6.4 GENFIT SA
6.5 Allergan
6.6 Gilead Science Inc.
6.7 Zydus Cadila
6.8 Immuron Ltd.
6.9 Conatus Pharmaceuticals
6.10 Novo Nordisk
6.11 Enzo Biochem, Inc.
6.12 Raptor Pharmaceuticals

Do Inquiry before Buying for research report: https://www.credenceresearch.com/inquiry-before-buying/58580

Medium Blog: https://medium.com/@kumarganesh028/non-alcoholic-steatohepatitis-market-is-expected-to-reach-worth-us-20-676-0-1e03884d06f2

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Media Contact

Name: Chris Smith

Address: 105 N 1st ST #429,

SAN JOSE, CA 95103 US

Toll-Free (US/CANADA) Ph.: +1-800-361-8290

E-mail:

Website: http://www.credenceresearch.com

# # #


Image Attached Image Attached Download file at: CA 95103, United States
(Right click and save file to download.)

Document Attached Image Attached Download file at: 95103
(Right click and save file to download.)

Submitted by Ganesh Kumar, Acute Market Reports on Friday, 12 July 2019 at 1:51 PM
Category: Business
 
Related News

Rapid Prototyping Service Company Announces To Offer Affordable Additive Manufacturing For Creating
Wednesday, 24 Jul 2019

Best wedding dresses at your disposal
Wednesday, 24 Jul 2019

Different Types of Inclinometers
Wednesday, 24 Jul 2019

The Chinese sky is the limit for the talented and hard-working pilots of world
Wednesday, 24 Jul 2019

Key Duties of Construction Employees
Wednesday, 24 Jul 2019

Related Events

Chief Data and Analytics Officer Singapore
Tuesday, 23 Jul 2019

St. Louis Business Cannabis Expo
Tuesday, 23 Jul 2019

Palo Alto Networks: Cyber Range - UK Public Sector
Thursday, 25 Jul 2019

Sup-X: The StartUp Expo
Thursday, 25 Jul 2019

Real Estate Workshop in Washington, D.C. - July 2019
Saturday, 27 Jul 2019

Latest News

Marfan Syndrome Treatment Market to Witness a Pronounce Growth by 2026
Wednesday, 24 Jul 2019

Gene Synthesis Market to Witness a Pronounce Growth by 2026
Wednesday, 24 Jul 2019

Cryotherapy Market Size, Share & Trend | Industry Analysis Report, 2026
Wednesday, 24 Jul 2019

Limb Salvage Surgery Market Overview and Regional Outlook Study 2018 – 2026
Wednesday, 24 Jul 2019

GnRH Agonists & Antagonists Market Size, Share & Trend | Industry Analysis Report, 2026
Wednesday, 24 Jul 2019

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2019
Today is Wednesday, 24 July 2019

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Neuropsychiatric Drug Development Summit Boston
  • Chief Data and Analytics Officer Singapore
  • St. Louis Business Cannabis Expo
  • Cardiovascular and Respiratory Disease Summit (CARPS)
  • 61st London International Youth Science Forum

  • Latest Jobs
    Sorry, there are currently no entries posted here.